Multi-task ADME/PK Prediction at Industrial Scale: Leveraging Large and Diverse Experimental Datasets

Moritz Walter,Jens Markus Borghardt,Lina Humbeck,Miha Skalic

DOI: https://doi.org/10.26434/chemrxiv-2024-pf4w9

2024-01-12

Abstract:ADME (Absorption, Distribution, Metabolism, Excretion) properties are key parameters to judge whether a drug candidate exhibits a desired pharmacokinetic (PK) profile. In this study, we tested multi-task machine learning (ML) models to predict ADME and animal PK endpoints trained on in-house data generated at Boehringer Ingelheim. Models were evaluated both at the design stage of a compound (i.e., no experimental data of test compounds available) and at testing stage when a particular assay would be conducted (i.e., experimental data of earlier conducted assays may be available). Using realistic time-splits, we found a clear benefit in performance of multi-task graph-based neural network models over single-task models, which was even stronger when experimental data of earlier assays is available. In an attempt to explain the success of multi-task models, we found that especially endpoints with the largest numbers of data points (physicochemical endpoints, clearance in microsomes) are responsible for increased predictivity in more complex ADME and PK endpoints. In summary, our study provides insight into how data for multiple ADME/PK endpoints in a pharmaceutical company can be best leveraged to optimize predictivity of ML models.

Chemistry

What problem does this paper attempt to address?

The main aim of this paper is to address the issue of predicting ADME/PK (Absorption, Distribution, Metabolism, Excretion/Pharmacokinetics) properties in the drug discovery process, particularly by applying multi-task machine learning models to large-scale datasets in the pharmaceutical industry to improve prediction performance.

Specifically, the research objectives include:

1. **Evaluating multi-task machine learning models**: Comparing the performance of multi-task graph neural network models with single-task models in predicting ADME and animal PK endpoints at different stages of drug discovery (design stage and testing stage).

2. **Utilizing temporal sequence information**: By considering the temporal sequence of experimental data (i.e., the time points at which compounds are tested), researchers can better simulate the real-world drug development process. This helps in understanding how to use existing data to improve prediction accuracy at different experimental stages (e.g., early in vitro experiments vs. later in vivo experiments).

3. **Exploring the role of auxiliary experiments**: Analyzing which early experimental data (such as in vitro metabolic stability) can significantly enhance the prediction capability for more complex ADME/PK properties (such as in vivo clearance).

4. **Optimizing machine learning models**: Optimizing the Chemprop model based on the message-passing neural network framework by adjusting hyperparameters and incorporating global molecular descriptors to further improve prediction performance.

5. **External validation**: Evaluating the generalization ability of the model through external validation using datasets from Biogen.

In summary, this paper attempts to improve the prediction accuracy of ADME/PK properties in the drug discovery process by developing and evaluating multi-task machine learning models, particularly for large and diverse experimental datasets.